Clinical Trials and Outcomes for Non-Small Cell Lung Cancer

Dear Colleagues,

Non-Small Cell Lung Cancer (NCLC) treatment has changed dramatically in the last 2.5 decades. We evolved from an armamentarium that was limited to surgery, radiotherapy and chemotherapy, chosen according to the histologic subtype, to the integration of these with target therapies, immunotherapy, and combination of different systemic treatments, according to the presence of actionable oncogenic alterations and other biomarkers. The number of trials for NSCLC, in the early or advanced setting is increasing exponentially and rapidly, compromising the head-to-head comparations, as well comparations with a standard of care that is in permanent evolution. Furthermore, it has becoming of utmost importance the observation of the clinical trial results in the real-world daily clinics, and the publication of that real world data, particularly in special populations, like elderly or with ECOG PS 2. For the clinician it is a challenge to be updated with this fast-moving reality, instigated by an unprecedent drug development, the new paradigm of trial designs, new targets and biomarkers.

The aim of this issue is to divulgate and integrate clinical trials and outcomes in the knowledge of NSCLC treatment, specially translating these results for our daily practice.

We are pleased to invite you to collaborate with us.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: clinical trials, real world data and reviews.

We look forward to receiving your contributions.

Dr. Ana Rodrigues
Prof. Dr. António Araújo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.